LexisNexis® Legal Newsroom
Scios To Plead Guilty, Pay $85 Million For Off-Label Marketing Of Natrecor

SAN FRANCISCO -- The Scios Inc. subsidiary of Johnson & Johnson has agreed to plead guilty to a misdemeanor charge related to the off-label marketing of its Natrecor heart drug, to pay an $85 million fine and to serve three years' organizational probation, according to a brief filed Sept. 14...

Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases

NEW BRUNSWICK, N.J. - (Mealey's) Johnson & Johnson (J&J) expects to incur a special charge against earnings of about $600 million in the second quarter for the potential settlement of civil litigation related to Risperdal, Invega, Natrecor and Omnicare Inc., according to a Form 8-K report...